TMS for tinnitus: what 20 years of research has shown

Repetitive transcranial magnetic stimulation (rTMS) has been investigated as a treatment for chronic tinnitus for more than two decades, producing one of the largest bodies of evidence for any physical intervention in this field. The results are more complicated than either proponents or critics often acknowledge: effects exist in a subset of patients, are typically modest in magnitude, and tend to decay after the treatment course ends. Understanding what the evidence does and does not show is important for anyone considering rTMS or evaluating it as a clinical option.

What TMS is and how it works

Transcranial magnetic stimulation uses a coil placed against the scalp to generate brief, focused magnetic field pulses that induce small electrical currents in the underlying cortical tissue. When delivered repetitively at specific frequencies, it can either increase or decrease cortical excitability in the target area.

In depression treatment, rTMS is typically applied to the left dorsolateral prefrontal cortex at high frequency (10 Hz), which increases excitability. For tinnitus, the primary target is the auditory cortex, usually the left temporoparietal cortex, most often using low-frequency stimulation (1 Hz) that aims to reduce excitability. The rationale is that chronic tinnitus is associated with hyperactivity and altered synchrony in the auditory cortex, and that reducing this activity would attenuate the phantom percept.

Some protocols target additional or alternative sites, including the secondary auditory cortex, the left prefrontal cortex, or combinations of sites based on neuroimaging data from individual patients. There is no single universally accepted protocol.

What the trials show

The overall picture from more than 30 randomized controlled trials and multiple meta-analyses is one of modest but statistically detectable benefit in a proportion of participants. Key findings from systematic reviews include:

Effect sizes are small to moderate: Mean improvements in Tinnitus Handicap Inventory (THI) scores in active rTMS groups typically exceed those in sham groups, but by modest margins. Clinically meaningful response, usually defined as a THI reduction of at least 7 points, is seen in roughly 25 to 40 percent of treated patients in well-controlled trials.

Effects decay after treatment: Most trials that include follow-up assessments show partial regression of benefit after the treatment course ends. Some studies find effects largely gone at 6 to 12 months. Booster session protocols are being explored but have not been standardized.

Responder prediction is limited: Baseline characteristics that predict response have been studied but no reliable predictor has emerged. Shorter tinnitus duration, less severe hearing loss, and left-lateralized tinnitus have been associated with better response in some analyses, but these associations are not consistent enough to guide clinical selection.

Sham response is substantial: Placebo response in tinnitus trials is consistently high, sometimes approaching or equaling the active treatment response. This makes double-blinding critical, and genuine blinding in rTMS trials is imperfect because participants can feel the stimulation differently in sham versus active conditions.

Regulatory status

In the United States, rTMS does not have FDA clearance for the tinnitus indication as of 2024. It is cleared for treatment-resistant major depressive disorder and for obsessive-compulsive disorder. Tinnitus use is off-label, which means it can be prescribed by a physician but is not covered by insurance for that indication, and the standard of regulatory evidence for efficacy has not been met.

In Europe, at least one rTMS device has received CE marking with a tinnitus indication, and the treatment is available in some specialist centers and private clinics. The regulatory divergence reflects both the different approval standards across jurisdictions and the genuine uncertainty in the evidence base.

The AAO-HNS 2014 tinnitus clinical practice guideline does not recommend rTMS as a standard of care, citing insufficient evidence, though the guideline acknowledges ongoing research.

The treatment experience

An rTMS session for tinnitus typically lasts 20 to 40 minutes. The patient sits or reclines with a coil held against the scalp. Low-frequency (1 Hz) stimulation delivers single pulses at one-second intervals. The sound and sensation are distinctive: a clicking noise with each pulse and a mild tapping sensation on the scalp. Headache and local discomfort are the most common adverse effects.

Standard protocols involve 10 to 20 daily sessions over two to four weeks. The time and financial commitment is substantial, particularly given the absence of insurance coverage for this indication in most markets.

Contraindications and safety

rTMS has a well-established safety record from large-scale clinical use in depression. Absolute contraindications relevant to tinnitus patients include metallic implants in or near the head, cochlear implants (the magnetic field could potentially damage or displace them), and active epilepsy or a history of seizures. Cochlear implants are particularly significant because many tinnitus patients have associated hearing loss that might otherwise make them candidates for implantation, creating a contraindication for rTMS if they already have one in place.

The seizure risk with properly conducted rTMS is very low, estimated at less than 1 in 10,000 sessions in depression populations. Patients with conditions that lower seizure threshold require careful evaluation before proceeding.

Current position in tinnitus care

rTMS occupies a contested position in tinnitus management. It has more controlled-trial evidence than most other pharmacological or device-based tinnitus interventions, but that evidence remains insufficient to support broad clinical recommendation. It is most defensible as an option for patients with severe, refractory chronic tinnitus who have not responded to evidence-based first-line approaches, specifically cognitive behavioral therapy and structured sound therapy.

Patients considering rTMS should seek a clinician with specific experience in tinnitus rTMS protocols, understand that response is not predictable and that effects may be temporary, and be aware of the regulatory and insurance status in their location.

If symptoms persist or change, see an audiologist or physician.